Literature DB >> 16720560

Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia.

Akane Kunitomi1, Takayuki Ishikawa, Kenichirou Tajima, Yoshiteru Konaka, Masato Yagita.   

Abstract

We describe a patient with Wegener granulomatosis (WG) who underwent long-term cyclophosphamide treatment and thereafter developed acute myelogenous leukemia (AML). After the AML was induced into remission, the patient received an allogeneic stem cell transplant (allo-SCT) from his sibling after undergoing a reduced-intensity conditioning regimen. His clinical course shortly after allo-SCT was uneventful. No clinically apparent acute or chronic graft-versus-host disease developed. Repeated analysis of the peripheral blood lymphocytes after transplantation showed complete donor chimerism. The level of proteinase 3 antineutrophil cytoplasmic antibody (PR3-ANCA) remained undetectable until 4 months after transplantation, when it began to increase. When the level of PR3-ANCA peaked, the patient suddenly presented with fever and joint pain, which later spontaneously resolved in parallel with the declining titer of PR3-ANCA. He is now in remission for both AML and WG at 22 months after transplantation. The patient's clinical course after allo-SCT may provide us with valuable information regarding the establishment of allo-SCT as a therapeutic option for WG.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720560     DOI: 10.1532/IJH97.05148

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

Review 1.  Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens.

Authors:  R A Nash
Journal:  Bone Marrow Transplant       Date:  2003-08       Impact factor: 5.483

2.  Therapy-related leukaemia in Wegener's granulomatosis.

Authors:  K Lee; T P Baglin; R E Marcus
Journal:  Clin Lab Haematol       Date:  1991

3.  Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  S J Martin; M A Audrain; F Oksman; M Ecoiffier; M Attal; N Milpied; V L Esnault
Journal:  Bone Marrow Transplant       Date:  1997-07       Impact factor: 5.483

4.  Wegener granulomatosis.

Authors:  C A Langford
Journal:  Am J Med Sci       Date:  2001-01       Impact factor: 2.378

5.  Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases.

Authors:  W Hinterberger; M Hinterberger-Fischer; A Marmont
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

6.  Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.

Authors:  M Hänel; K Friedrichsen; A Hänel; R Herbst; A Morgner; S Neser; M Nicklisch; M Teich; G Ehninger; F Fiedler
Journal:  Onkologie       Date:  2001-08

Review 7.  Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective.

Authors:  R E Hough; J A Snowden; N M Wulffraat
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

8.  Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).

Authors:  Hiroya Tamaki; Machiko Mishima; Manabu Kawakami; Akihiro Tsuboi; Eui Ho Kim; Naoki Hosen; Kazuhiro Ikegame; Masaki Murakami; Tatsuya Fujioka; Tomoki Masuda; Yuki Taniguchi; Sumiyuki Nishida; Kazuoki Osumi; Toshihiro Soma; Yusuke Oji; Yoshihiro Oka; Ichiro Kawase; Haruo Sugiyama; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases.

Authors:  S D Michels; R W McKenna; D C Arthur; R D Brunning
Journal:  Blood       Date:  1985-06       Impact factor: 22.113

Review 10.  Conventional treatment and outcome of Wegener's granulomatosis and microscopic polyangiitis.

Authors:  David R W Jayne
Journal:  Cleve Clin J Med       Date:  2002       Impact factor: 2.321

View more
  6 in total

Review 1.  Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes.

Authors:  Gabriella Fleixo-Lima; Hilla Ventura; Michal Medini; Liliana Bar; Pnina Strauss; Eli C Lewis
Journal:  J Diabetes Sci Technol       Date:  2014-08-25

2.  Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature.

Authors:  Thomas Daikeler; Ina Kötter; Chiara Bocelli Tyndall; Jane Apperley; Andishe Attarbaschi; Philippe Guardiola; Alois Gratwohl; Esa Jantunen; Alberto Marmont; Ferdinando Porretto; Maurizio Musso; Britta Maurer; Nadia Rinaldi; Riccardo Saccardi; Alan Tyndall
Journal:  Ann Rheum Dis       Date:  2006-09-01       Impact factor: 19.103

Review 3.  Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.

Authors:  O Guttman; B M Baranovski; R Schuster; Z Kaner; G S Freixo-Lima; N Bahar; N Kalay; M I Mizrahi; I Brami; D E Ochayon; E C Lewis
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

Review 4.  Stem cell autograft and allograft in autoimmune diseases.

Authors:  Angelo De Cata; Angela Matarangolo; Michele Inglese; Rosa Rubino; Gianluigi Mazzoccoli
Journal:  Clin Exp Med       Date:  2014-12-14       Impact factor: 3.984

Review 5.  An update on stem cell transplantation in autoimmune rheumatologic disorders.

Authors:  Sheryl Mascarenhas; Belinda Avalos; Stacy P Ardoin
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

6.  Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.

Authors:  J A Snowden; R Saccardi; M Allez; S Ardizzone; R Arnold; R Cervera; C Denton; C Hawkey; M Labopin; G Mancardi; R Martin; J J Moore; J Passweg; C Peters; M Rabusin; M Rovira; J M van Laar; D Farge
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.